Journal
JNP-JOURNAL FOR NURSE PRACTITIONERS
Volume 13, Issue 6, Pages 418-424Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.nurpra.2016.08.023
Keywords
GLP-1 receptor agonists; DPP-4 inhibitors; incretin therapy; primary care; type 2 diabetes mellitus
Categories
Ask authors/readers for more resources
Glucagon-like peptide-1 receptor agonists and dipeptidyl-peptidase 4 inhibitors ate 2 of 6 second-line medication options in diabetes management according to the 2016 American Diabetes Association guidelines. Providers must take many factors into consideration when choosing a tteatment regimen, including patient preference, cost and insurance coverage, efficacy, and tolerability. Side effects, such as hypoglycemia and weight gain; often contribute to lack of control and poor adherence. Glucagon-like peptide-1 receptor agonists and dipeptidyl-peptidase 4 inhibitors are well tolerated options that improve glycemic control with a low incidence of hypoglycemia and weight gain. In this article we review the similarities, differences, advantages, and disadvantages of the incretin therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available